Epirubicin in colorectal cancer - A phase II study of the early clinical trials group (EORTC)

Eduard E. Holdener, Heine H. Hansen, Hans Høst, Uta Bruntsch, Franco Cavalli, Josette Renard, Herbert M. Pinedo, Marcel Rozencweig

Research output: Contribution to journalArticlepeer-review

Abstract

Epirubicin, a stereoisomer of doxorubicin with suggested lower potential for cardiotoxicity in experimental animal tumor systems, was studied in a disease-oriented phase II trial in patients with advanced colorectal cancer. The drug was given as a direct iv injection of 90 mg/m2 q 3 weeks. No objective response was observed in 52 evaluable patients with colon (n = 34) and rectal (n = 18) carcinoma. Fourteen patients (27%) had stable disease for a median of four treatment courses. Leukopenia (88%), nausea and vomiting (71%) and alopecia (54%) were the most common toxic effects. We conclude that epirubicin at the present dose and schedule is an ineffective agent in patients with metastatic colorectal cancer.

Original languageEnglish (US)
Pages (from-to)63-66
Number of pages4
JournalInvestigational New Drugs
Volume3
Issue number1
DOIs
StatePublished - Mar 1985
Externally publishedYes

Keywords

  • colorectal cancer
  • epirubicin

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Epirubicin in colorectal cancer - A phase II study of the early clinical trials group (EORTC)'. Together they form a unique fingerprint.

Cite this